An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in France

This article or press release has no online content. Please download the associated documents for more information.

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria

Ipsen delivers FY and Q4 2022 results – A word from CEO David Loew

Choose your location: